{"id":"W2977739337","doi":"10.1093/annonc/mdz244.036","title":"Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Carboplatin; Tolerability; Internal medicine; Chemotherapy; Gemcitabine; Pemetrexed; Vinorelbine; Oncology; Cisplatin; Adverse effect; Cancer; Immunotherapy; Pembrolizumab; Ipilimumab","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002034273,0.0008279652,0.002228147,0.0004221967,0.0004049016,0.001025648,0.0008194564,0.0004758003,0.001500441],"category_scores_gemma":[0.002285937,0.0003719479,0.001489681,0.001149604,0.0004151367,0.0005449021,0.0002325458,0.002182891,0.0003991018],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005633042,"about_ca_system_score_gemma":0.005878446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.09672839,"about_ca_topic_score_gemma":0.2189022,"domain_scores_codex":[0.9989951,0.0002622215,0.00005278631,0.0001362808,0.000381371,0.0001723174],"domain_scores_gemma":[0.9989587,0.0002281707,0.000290031,0.0001268683,0.0001592158,0.0002370686],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6072808,0.004355162,0.07881337,0.001801309,0.01088139,0.0004058227,0.0002953944,0.01284815,0.02008291,0.0006913871,0.02197504,0.2405694],"study_design_scores_gemma":[0.160749,0.05459577,0.7167538,0.0001768037,0.01128696,0.001075764,0.0001053691,0.00513805,0.004979952,0.0006033453,0.04432951,0.0002057638],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9588103,0.0117861,0.0008440941,0.0006919787,0.0001158434,0.0007402209,0.01923863,0.0001354229,0.00763744],"genre_scores_gemma":[0.9718112,0.003902825,0.0009644649,0.0005928221,0.00008599035,0.0003096351,0.01959853,0.00004178081,0.002692819],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09672839,"threshold_uncertainty_score":0.1923307,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1648131909296179,"score_gpt":0.4216233194782329,"score_spread":0.256810128548615,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}